Dimitrokalli, Evangelia; Fertaki, Stefani; Lykouras, Michail; Kokkinos, Petros; Orkoula, Malvina; Kontoyannis, Christos published an article in 2021, the title of the article was Warfarin Sodium Stability in Oral Formulations.Product Details of 585-88-6 And the article contains the following content:
Warfarin sodium is a low-dose pharmaceutical blood thinner that exists in two forms: the clathrate form and the amorphous form. In com. available warfarin sodium oral suspension, the active pharmaceutical ingredient (API) is added in the amorphous state. This study investigates the apparent instability of the com. available warfarin liquid oral formulation using Raman and IR spectroscopy, X-ray diffraction, differential scanning calorimetry, UV spectroscopy, and optical microscopy. Warfarin, not its sodium salt, was identified as the undissolved solid existing in the suspension. This was found to be due to the dissociation of sodium salt and the protonation of the warfarin ion in the liquid phase, which triggered the crystallization of the sparingly soluble unsalted form. The coexistence of protonated and unprotonated warfarin ions in the supernatant, as detected by Raman and UV spectroscopy, confirmed this assumption. Study of the dissolution of warfarin sodium amorphous salt and crystalline sodium clathrate in the placebo and pure water verified the results. The effect of pH and temperature on warfarin precipitation was also explored. The experimental process involved the reaction of SweetPearlR P300 DC Maltitol(cas: 585-88-6).Product Details of 585-88-6
The Article related to warfarin sodium stability oral formulation, dsc, ir, raman spectroscopy, x-ray powder diffraction, crystallization, oral suspension, warfarin, warfarin clathrate, warfarin sodium amorphous and other aspects.Product Details of 585-88-6
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts